

## Overview

**Useful For**

Pre-analysis cell sorting for the MayoComplete Plasma Cell Myeloma panel

**Method Name**

Only orderable as a reflex. For more information see NGPCM / MayoComplete Plasma Cell Myeloma, Next-Generation Sequencing, Varies.

Flow Cytometric Cell Selection

**NY State Available**

No

## Specimen

**Specimen Type**

Bone Marrow

**Specimen Required**

Only orderable as a reflex. For more information see NGPCM / MayoComplete Plasma Cell Myeloma, Next-Generation Sequencing, Varies.

**Container/Tube:** Lavender or pink top (EDTA) or yellow top (ACD)

**Specimen Volume:** 2 mL

**Collection Instructions:**

1. Minimum plasma cell percentage is 1%.
2. Invert several times to mix bone marrow.
3. Send bone marrow specimen in original tube. **Do not aliquot.**
4. Label specimen as bone marrow.
5. **Fresh specimen is required for this test**, as testing is performed on sorted cells.

**Specimen Minimum Volume**

2 mL

**Reject Due To**

Gross hemolysis	Reject
Gross lipemia	OK

Fully clotted	Reject
Bone marrow biopsies	Reject
Slides	Reject
Paraffin shavings	Reject
Frozen tissues	Reject
Paraffin-embedded tissues	Reject
Paraffin-embedded bone marrow aspirates	Reject
Extracted DNA	Reject

### Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
Bone Marrow	Ambient	4 days	

### Clinical & Interpretive

#### Clinical Information

Testing allows for further risk categorization of multiple myeloma (MM) through identifying additional abnormalities of prognostic and, potentially, therapeutic value. Application of targeted next-generation sequencing-based analysis is a useful adjunct to the standard evaluation of MM patients at diagnosis and relapse.

#### Reference Values

Only orderable as a reflex. For more information see NGPCM / MayoComplete Plasma Cell Myeloma, Next-Generation Sequencing, Varies.

Not applicable

#### Interpretation

Correlation with clinical, histopathologic, and additional laboratory findings is required for final interpretation of these results. The final interpretation of results for clinical management of the patient is the responsibility of the managing physician.

#### Cautions

No significant cautionary statements

#### Clinical Reference

1. Walker BA, Boyle EM, Wardell CP, et al. Mutational spectrum, copy number changes, and outcome: results of a

sequencing study of patients with newly diagnosed myeloma. *J Clin Oncol.* 2015;33(33):3911-3920

2. Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. *Nat Rev Cancer.* 2012;12(5):335-348
3. Kortuem KM, Braggio E, Bruins L, et al. Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients. *Blood Cancer J.* 2016;6(2):e397
4. Kortuem KM, Mai EK, Hanafiah NH, et al. Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. *Blood.* 2016;128(9):1226-1233

## Performance

### Method Description

Selection of plasma cells using fluorescence-activated cell sorting is the most direct and robust method of obtaining relatively pure plasma cell populations for molecular assessment. This, in turn, augments the ability to identify key mutations and subclonal variants of possible clinical value without dilution effects from non-tumor cell DNA. (Instruction manual: BD FACSMelody Cell Sorter User's Guide. Revision 3. BD Biosciences; 03/2020)

### PDF Report

No

### Day(s) Performed

Monday through Saturday

### Report Available

1 to 2 days

### Specimen Retention Time

DNA: 3 months

### Performing Laboratory Location

Mayo Clinic Laboratories - Rochester Main Campus

## Fees & Codes

### Fees

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

### Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

**CPT Code Information**

88184-Flow Cytometry; first cell surface, cytoplasmic or nuclear marker

88185 x 5-Flow Cytometry, additional cell surface, cytoplasmic or nuclear marker (each)

**LOINC® Information**

Test ID	Test Order Name	Order LOINC® Value
CSPMM	NGPCM Pre-Analysis Cell Sorting, BM	No LOINC Needed

Result ID	Test Result Name	Result LOINC® Value
618627	NGPCM Pre-Analysis Cell Sort	No LOINC Needed
618630	Final Diagnosis	22637-3